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Methods that allow high throughput identification of cellular targets of biologically active small 
molecules are valuable assets in pharmaceutical research. They are useful in mechanism of action 
studies of hits identified via phenotypic screening. Alternatively, they may uncover ‘off-target’ 
proteins of established drugs, that may contribute to their therapeutic efficacy or unwanted side 
effects. Finally, such methods also allow to identify potential novel therapeutic applications of 
existing drugs. 
 
MAmmalian Small molecule-Protein Interaction Trap (MASPIT) is a three-hybrid approach that 
enables swift proteome-wide screening for intracellular targets of small molecules based on the 
JAK/STAT signaling pathway of the cytokine receptor (CR).1 MASPIT employs DHFR, fused to the CR to 
present a methotrexate (MTX) fusion compound (MFC) to the intracellular environment. This allows 
the screening of a small molecule bait against a collection of chimeric prey proteins. As a result of the 
interaction between the bait and a prey protein, the JAK/STAT pathway is activated, resulting in the 
expression of the luciferase reporter gene. 
 
A conditio sine qua non for successful MASPIT analysis is the availability of appropriate synthetic 
probes.2 In this presentation we will discuss our efforts in optimizing the MASPIT system’s selectivity 
and sensitivity via the synthesis and biological evaluation of tamoxifen-fusion compounds, 
comprising immobilizing moieties different from the known MTX anchor.  
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